Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dermavant Sciences GmbHfiledCriticalDermavant Sciences GmbH
Publication of AR117386A1publicationCriticalpatent/AR117386A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Medicinal Preparation
(AREA)
Abstract
Se revelan formas de realización de formulaciones tópicas para la administración de cerdulatinib o una sal aceptable para uso farmacéutico, hidrato o solvato del mismo. También se revelan formas de realización de métodos para la preparación de las formulaciones tópicas. Las formulaciones reveladas son adecuadas para el tratamiento de afecciones dermatológicas tales como la dermatitis atópica.Topical formulations embodiments are disclosed for the administration of cerdulatinib or a pharmaceutically acceptable salt, hydrate or solvate thereof. Method embodiments for the preparation of the topical formulations are also disclosed. The disclosed formulations are suitable for the treatment of dermatological conditions such as atopic dermatitis.
ARP190100042A2018-01-092019-01-09
TOPICAL PHARMACEUTICAL COMPOSITIONS FOR THE SKIN CONTAINING CERDULATINIB AND USES THEREOF
AR117386A1
(en)
A pyridine derivative represented by formulas i to iii and a pharmaceutically acceptable salt thereof; preparation process of the pyridine derivative or the pharmaceutically acceptable salt thereof; pharmaceutical composition and its use to prepare a medicament useful for the prevention or treatment of an abnormal cell growth disease caused by a ras mutation.
COMBINATIONS OF A N-TIAZOLIL-4-PHENOXIBENCENOSULFONAMIDE DERIVATIVE AND A PHARMACEUTICALLY ACTIVE AGENT SELECTED FROM GABAPENTINE AND PREGABALINE TO TREAT PAIN